Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Rhea-AI Summary
Profound Medical (NASDAQ:PROF) announced management will present an update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 22, 2026 at 10:00 a.m. ET at the Metro Toronto Convention Centre.
The presentation will be broadcast live and archived on the company website under the Investors IR Calendar.
Positive
- None.
Negative
- None.
News Market Reaction – PROF
In the Apr 14 session, PROF declined 0.16%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | Clinical meeting exposure | Positive | +0.8% | TULSA-PRO featured in multiple presentations at SIR 2026 in Toronto. |
| Mar 27 | Clinical usage milestone | Positive | -1.8% | Texas Prostate reached 100th TULSA Procedure with 500% volume increase post-Medicare. |
| Mar 13 | Trial outcome update | Positive | -0.7% | CAPTAIN trial met primary safety endpoint favoring TULSA over radical prostatectomy. |
| Mar 09 | Investor events notice | Neutral | -1.5% | Planned CAPTAIN data call and participation in the ROTH investor conference. |
| Mar 05 | Earnings results | Negative | -29.1% | Record 2025 revenue but sizeable net loss and equity financings triggered sharp drop. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows several positive clinical and commercial updates followed by muted or negative one-day price reactions, while earnings-related weakness drew a larger selloff.
Over the past months, Profound Medical has highlighted growing clinical and commercial traction. On Mar 5, 2026, it reported record Q4-2025 revenue of $6.0M and $16.1M for full year 2025, an installed base of 78 systems, and a pipeline of 110 potential systems, yet shares fell 29.11%. Subsequent news emphasized CAPTAIN trial success and TULSA usage milestones, with generally modest price moves. The current conference participation fits an ongoing pattern of active clinical and investor engagement.
Key Terms
mri-guided medical
ablation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 22, 2026 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre.
The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "IR Calendar" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures, enabling precise, incision-free therapies that improve clinical confidence, procedural control, and patient outcomes. By leveraging real-time MRI guidance, Profound’s technologies are designed to replace uncertainty with clarity across treatment planning, delivery, and confirmation.
The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate therapy designed for precision and flexibility. The TULSA Procedure™ allows physicians to see, treat, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care for the full spectrum of prostate disease, including prostate cancer and/or benign prostatic hyperplasia (BPH), while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.
Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.
Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared or approved in the United States, Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE, while Sonalleve is cleared or approved in the United States (HDE), Europe, Canada, China, and Saudi Arabia.
Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
